TLSI News
TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
TriSalus Life Sciences Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David...
Business Wire
TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
TriSalus Life Sciences Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David...
Business Wire
Verano Holdings Corp. (VRNO) Reports Q3 Loss, Lags Revenue Estimates
Verano Holdings Corp. (VRNO) delivered earnings and revenue surprises of +50.00% and -1.61%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced that it will host a conference call and...
Business Wire
TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support
TriSalus Life Sciences secured FDA clearance for its TriNav Advance device, but shares face critical resistance levels amid a recent slide.read more...
Benzinga
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.read more...
Benzinga
TriSalus Lands Key FDA Clearance as PEDD Platform Pushes into Tougher Anatomy
TriSalus Life Sciences (NASDAQ:TLSI) cleared a regulatory hurdle that could materially broaden the reach of its Pressure-Enabled Drug Delivery platform.
24-7 Market News
TriSalus Life Sciences Receives FDA Clearance for TriNav Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery (PEDD) Portfolio for Liver Embolization
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard-of-care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced it has received U.S. Food and Drug...
Business Wire
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
TriSalus Life Sciences Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David...
Business Wire
TriSalus Life Sciences Q2 Earnings Call Highlights
TriSalus Life Sciences Q2 Earnings Call Highlights...
Yahoo! Finance: News
TriSalus Life Sciences Reports Second Quarter 2026 Results
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter...
Business Wire